728 related articles for article (PubMed ID: 26571089)
21. Effects of fenofibrate and xuezhikang on high-fat diet-induced non-alcoholic fatty liver disease.
Hong XZ; Li LD; Wu LM
Clin Exp Pharmacol Physiol; 2007; 34(1-2):27-35. PubMed ID: 17201732
[TBL] [Abstract][Full Text] [Related]
22. Monascin and ankaflavin act as natural AMPK activators with PPARα agonist activity to down-regulate nonalcoholic steatohepatitis in high-fat diet-fed C57BL/6 mice.
Hsu WH; Chen TH; Lee BH; Hsu YW; Pan TM
Food Chem Toxicol; 2014 Feb; 64():94-103. PubMed ID: 24275089
[TBL] [Abstract][Full Text] [Related]
23. Magnesium isoglycyrrhizinate blocks fructose-induced hepatic NF-κB/NLRP3 inflammasome activation and lipid metabolism disorder.
Zhao XJ; Yang YZ; Zheng YJ; Wang SC; Gu HM; Pan Y; Wang SJ; Xu HJ; Kong LD
Eur J Pharmacol; 2017 Aug; 809():141-150. PubMed ID: 28526339
[TBL] [Abstract][Full Text] [Related]
24. Ameliorative effect of nicorandil on high fat diet induced non-alcoholic fatty liver disease in rats.
Elshazly SM
Eur J Pharmacol; 2015 Feb; 748():123-32. PubMed ID: 25542756
[TBL] [Abstract][Full Text] [Related]
25. Effect of traditional Chinese medicine formula Sinisan on chronic restraint stress-induced nonalcoholic fatty liver disease: a rat study.
Cheng F; Ma C; Wang X; Zhai C; Wang G; Xu X; Mu J; Li C; Wang Z; Zhang X; Yue W; Du X; Lian Y; Zhu W; Yin X; Wei Z; Song W; Wang Q
BMC Complement Altern Med; 2017 Apr; 17(1):203. PubMed ID: 28388904
[TBL] [Abstract][Full Text] [Related]
26. The effects of herbal composition Gambigyeongsinhwan (4) on hepatic steatosis and inflammation in Otsuka Long-Evans Tokushima fatty rats and HepG2 cells.
Yoon S; Kim J; Lee H; Lee H; Lim J; Yang H; Shin SS; Yoon M
J Ethnopharmacol; 2017 Jan; 195():204-213. PubMed ID: 27845265
[TBL] [Abstract][Full Text] [Related]
27. Hepatoprotective effect of calculus bovis sativus on nonalcoholic fatty liver disease in mice by inhibiting oxidative stress and apoptosis of hepatocytes.
He W; Xu Y; Zhang C; Lu J; Li J; Xiang D; Yang J; Chang M; Liu D
Drug Des Devel Ther; 2017; 11():3449-3460. PubMed ID: 29255346
[TBL] [Abstract][Full Text] [Related]
28. Alpha-naphthoflavone attenuates non-alcoholic fatty liver disease in oleic acid-treated HepG2 hepatocytes and in high fat diet-fed mice.
Xia H; Zhu X; Zhang X; Jiang H; Li B; Wang Z; Li D; Jin Y
Biomed Pharmacother; 2019 Oct; 118():109287. PubMed ID: 31401392
[TBL] [Abstract][Full Text] [Related]
29. Chronic treatment with the modified Longdan Xiegan Tang attenuates olanzapine-induced fatty liver in rats by regulating hepatic de novo lipogenesis and fatty acid beta-oxidation-associated gene expression mediated by SREBP-1c, PPAR-alpha and AMPK-alpha.
Ren L; Sun D; Zhou X; Yang Y; Huang X; Li Y; Wang C; Li Y
J Ethnopharmacol; 2019 Mar; 232():176-187. PubMed ID: 30590197
[TBL] [Abstract][Full Text] [Related]
30. The Chinese medicine Chai Hu Li Zhong Tang protects against non-alcoholic fatty liver disease by activating AMPKα.
Zhang M; Yuan Y; Wang Q; Li X; Men J; Lin M
Biosci Rep; 2018 Dec; 38(6):. PubMed ID: 30291215
[TBL] [Abstract][Full Text] [Related]
31. Artemisia capillaris formula inhibits hepatic steatosis via an miR‑122‑induced decrease in fatty acid synthase expression in vivo and in vitro.
Liu L; Zhao J; Li Y; Wan Y; Lin J; Shen A; Xu W; Li H; Zhang Y; Xu J; Peng J; Hong Z
Mol Med Rep; 2016 Jun; 13(6):4751-8. PubMed ID: 27081834
[TBL] [Abstract][Full Text] [Related]
32. Gastrodin Ameliorates Oxidative Stress and Proinflammatory Response in Nonalcoholic Fatty Liver Disease through the AMPK/Nrf2 Pathway.
Qu LL; Yu B; Li Z; Jiang WX; Jiang JD; Kong WJ
Phytother Res; 2016 Mar; 30(3):402-11. PubMed ID: 26634892
[TBL] [Abstract][Full Text] [Related]
33. Demethyleneberberine attenuates non-alcoholic fatty liver disease with activation of AMPK and inhibition of oxidative stress.
Qiang X; Xu L; Zhang M; Zhang P; Wang Y; Wang Y; Zhao Z; Chen H; Liu X; Zhang Y
Biochem Biophys Res Commun; 2016 Apr; 472(4):603-9. PubMed ID: 26970305
[TBL] [Abstract][Full Text] [Related]
34. Wogonin mitigates nonalcoholic fatty liver disease via enhancing PPARα/AdipoR2, in vivo and in vitro.
Chen J; Liu J; Wang Y; Hu X; Zhou F; Hu Y; Yuan Y; Xu Y
Biomed Pharmacother; 2017 Jul; 91():621-631. PubMed ID: 28486193
[TBL] [Abstract][Full Text] [Related]
35. Huangkui capsule, an extract from Abelmoschus manihot (L.) medic, improves diabetic nephropathy via activating peroxisome proliferator-activated receptor (PPAR)-α/γ and attenuating endoplasmic reticulum stress in rats.
Ge J; Miao JJ; Sun XY; Yu JY
J Ethnopharmacol; 2016 Aug; 189():238-49. PubMed ID: 27224243
[TBL] [Abstract][Full Text] [Related]
36. Hesperetin ameliorates hepatic oxidative stress and inflammation
Li J; Wang T; Liu P; Yang F; Wang X; Zheng W; Sun W
Food Funct; 2021 May; 12(9):3898-3918. PubMed ID: 33977953
[TBL] [Abstract][Full Text] [Related]
37. Ginsenoside Rg1 Protects against Non-alcoholic Fatty Liver Disease by Ameliorating Lipid Peroxidation, Endoplasmic Reticulum Stress, and Inflammasome Activation.
Xu Y; Yang C; Zhang S; Li J; Xiao Q; Huang W
Biol Pharm Bull; 2018 Nov; 41(11):1638-1644. PubMed ID: 30135326
[TBL] [Abstract][Full Text] [Related]
38. Isobaric tags for relative and absolute quantitation (iTRAQ)-based proteomics for the investigation of the effect of Hugan Qingzhi on non-alcoholic fatty liver disease in rats.
Yao X; Xia F; Tang W; Xiao C; Yang M; Zhou B
J Ethnopharmacol; 2018 Feb; 212():208-215. PubMed ID: 29031784
[TBL] [Abstract][Full Text] [Related]
39. Oxymatrine ameliorates non-alcoholic fatty liver disease in rats through peroxisome proliferator-activated receptor-α activation.
Shi L; Shi L; Zhang H; Hu Z; Wang C; Zhang D; Song G
Mol Med Rep; 2013 Aug; 8(2):439-45. PubMed ID: 23754536
[TBL] [Abstract][Full Text] [Related]
40. Regulatory effect of a Chinese herbal medicine formula on non-alcoholic fatty liver disease.
Yang JM; Sun Y; Wang M; Zhang XL; Zhang SJ; Gao YS; Chen L; Wu MY; Zhou L; Zhou YM; Wang Y; Zheng FJ; Li YH
World J Gastroenterol; 2019 Sep; 25(34):5105-5119. PubMed ID: 31558860
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
